<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 10 (filtered)">
<title>ePharmaceuticals </title>

<style>
<!--
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:windowtext;}
h1
	{margin-right:0in;
	margin-left:0in;
	font-size:24.0pt;
	font-family:"Times New Roman";
	color:black;
	font-weight:bold;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:black;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;}
div.Section1
	{page:Section1;}
-->
</style>

</head>

<body lang=EN-US>

<div class=Section1>

<p class=MsoNormal style='margin-bottom:12.0pt'><b><span style='font-size:18.0pt;
font-family:Arial;color:black'>ePharmaceuticals</span></b><span
style='color:black'> <br>
</span><b><span style='font-size:10.0pt;font-family:Arial;color:black'>1/19/2004</span></b><span
style='color:black'> <br>
<br>
</span></p>

<p class=MsoNormal><b><span style='font-size:24.0pt;color:black'>Lilly MedTech
Venture Fund launched</span></b></p>

<p class=MsoNormal><span style='font-size:10.0pt;font-family:Arial;color:black'>Marketletter
via NewsEdge Corporation : American pharmaceutical giant Eli Lilly &amp; Co has
reported the launch of the Lilly MedTech Venture Fund, the third venture
capital fund to be managed by Lilly Ventures, the company's corporate venture
arm. Lilly MedTech Venture Fund has an initial commitment of $50 million, the
addition of which will bring the total fund value managed by Lilly Venture to
$175 million. The Lilly MedTech Venture Fund aims to invest in companies
developing innovative technologies in the medical field, making initial
investments of up to $5 million per company.</span></p>

<p class=MsoNormal><span style='font-size:10.0pt;font-family:Arial;color:black'>The
Fund will primarily focus on the areas of diagnostics, therapeutic devices and
combination products to include pharmaceuticals, medical devices and/or
diagnostics. David Thompson, Lilly's vice president of corporate strategy and
business development, said: this new fund gives us an opportunity to leverage
our industry expertise in the development of these emerging, high-growth
segments of the health care industry, while Nick Colangelo, managing director
for Lilly Ventures, said: our goal is to provide capital and industry expertise
to accelerate the path to success and generate long-term capital gains for our
portfolio companies and their investors.</span></p>

<p class=MsoNormal><span style='font-size:10.0pt;font-family:Arial;color:black'>.end
(paragraph)&lt;&gt;</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Source: <i>Marketletter</i></span></p>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
